NY-DILIGENT
27.5.2021 19:09:08 CEST | Business Wire | Press release
Diligent Corporation , the global leader in SaaS governance, risk and compliance, today announced the addition of four new partners, all based in Spain – Esade Center for Corporate Governance , Fundación Woman Forward , Instituto de Gobernanza Empresarial and WomenCEO – in its growing Modern Leadership initiative, which was created to further increase diverse representation in global businesses at the executive and board levels.
These organizations are committed to promoting best corporate governance practices, including increasing diversity and inclusion. According to research conducted by the Diligent Institute , men currently hold approximately three times more board leadership positions than women. The Modern Leadership initiative, which seeks to improve this statistic, helps companies measure and report on diversity as a part of their environmental, social and governance strategy.
“Esade’s Center for Corporate Governance is deeply passionate about the role women play in business success and growth,” said Mario Lara, Director of Esade Madrid and the Center for Corporate Governance. “Progress in achieving equality at the board and senior leadership levels is still nowhere near the rate it should be, which is why global initiatives like Diligent’s Modern Leadership are vital in changing the landscape and trajectory for women leaders.”
The new Spanish organizations joining the Modern Leadership initiative include:
- Esade Center for Corporate Governance - The Center for Corporate Governance together with the Esade Alumni Club of Directors aims to become a leading reference center in the field of corporate governance in Spain. The Esade alumni network is the largest in Europe and one of the most expansive in the world, comprising over 60,000 members in 118 countries.
- Fundación Woman Forward - The foundation is a non-profit institution that promotes women empowerment, gender equality, and diversity, using training and research. Woman Forward encourages and helps to strengthen the role of women in business.
- Instituto de Gobernanza Empresarial - The Institute of Business Governance provides training and networking opportunities, and disseminates research to promote a business culture that is committed to corporate governance.
- WomenCEO - WomenCEO aims to make women visible in the boardroom while demonstrating the need for them to be counted on in economic and social spheres. The organization believes that women are influential, both on the board of directors and in management positions in companies and institutions.
“Closing the gender gap in leadership is a global challenge that we have a greater chance to solve with international coordination,” said Brian Stafford, CEO of Diligent. “This is why expanding Diligent’s Modern Leadership initiative to include these organizations and others like them is imperative. Together, we can use our networks to identify, present and fill leadership positions for diverse candidates in the region and beyond.”
Diligent is committed to driving diversity by enacting change at the board level. To learn more about Diligent’s Modern Leadership initiative, please visit https://diligentmodernleadership.com .
About Diligent Corporation
Diligent is the largest governance, risk and compliance (GRC) SaaS provider, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of audit, risk, information security, ethics and compliance across the organization.
Diligent brings technology, insights and confidence to leaders so they can build more effective, equitable and successful organizations. We empower 79% of the Fortune 500, 90% of the FTSE 100 and 83% of the ASX 200 to improve their bottom line, to keep pace with stakeholder expectations and to create a lasting, positive impact on the world.
For more information, visit www.diligent.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005765/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
